Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Primary Purpose
Smoking Cessation, Schizophrenia
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Combination Bupropion + NRTs
Extended Treatment
Home Visits & Calls
Monotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Smoking Cessation
Eligibility Criteria
Inclusion Criteria:
- Veterans 21 years of age or older;
- meet DSM-IV criteria for Schizophrenia or Schizoaffective disorder based on clinical interview
- meet DSM-IV criteria for nicotine dependence
- must report smoking >10 cigarettes daily and positive CO exhalation >8ppm
- seeking treatment for nicotine dependence;
- willing and able to comply with study procedures;
- willing and able to provide written informed consent;
- if female, not pregnant or lactating and willing to use a medically reliable method of birth control during the trial (e.g., birth control pills, Depo-Provera, and/or condoms with spermicide).
- Must be clinically stable (i.e., no inpatient hospitalizations for 3 months prior to enrollment, no changes in medication in the four weeks prior to enrollment)
Exclusion Criteria:
- current or past history of cardiovascular disease including myocardial infarction, acute coronary syndrome, angina pectoris, coronary artery disease, atrial fibrillation/flutter, cor pulmonale, arrhythmia other than sinus tachycardia or sinus bradycardia, or an EKG suggesting any of these;
- systolic blood pressure greater than 160 or diastolic blood pressure greater than 100 (i.e. cutoffs for stage 2 hypertension)
- a history of angioedema;
- renal impairment (CrCl < 50);
- a current neurological disorder (e.g., organic brain disease, dementia) or a medical history which would make study agent compliance difficult or which would compromise informed consent;
- a history of attempted suicide (lifetime) and/or suicidal ideation in the past year as assessed by the C-SSRS;
- currently on prescription medication that is contraindicated for use with bupropion;
- currently using any form of nicotine replacement therapy;
- current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by DSM-IV within the past 6 months;
- a history of sensitivity to bupropion or nicotine replacement;
- any history of seizures or seizure disorder;
- a history of serious head injury (ie, loss of consciousness longer than 1 hour, no neuropsychological sequelae, no cognitive rehabilitation treatment post head injury
- evidence of substance or alcohol dependence in the past six months; evidence of substance or alcohol abuse in the past month;
- sedatives or benzodiazepine use within 12 hours of testing based on urine toxicology screening
- history of mental retardation or developmental disability based on chart review
- psychiatric hospitalization during study participation
- history of an eating disorder
- have a medical condition that could be made worse by treatment with nicotine, including poorly controlled insulin dependent diabetes, uncontrolled hyperthyroidism, pheochromocytoma, severe oropharyngeal, esophageal, or peptic ulcer disease, or severe renal or hepatic impairment as determined via the baseline medical history and physical exam
- have an allergy to adhesive tape or latex or serious dermatologic disease (excluding minor skin conditions such as mild eczema) due to potential for skin allergy to patch
- have a known allergy to nicotine or any component of the nicotine patches
- be pregnant or sexually active and not using reliable birth control methods consistently (for females)
Sites / Locations
- West Los Angeles Veterans Affairs Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Experimental
Experimental
Arm Label
Standard Monotherapy
Combination Extended Treatment
Combination Extended Treatment + Home Visits/Calls
Arm Description
Treatment as usual starting with one smoking cessation medication plus group therapy.
Extended treatment with multiple standard medications plus group therapy.
Extended treatment with multiple standard medications plus group therapy plus home visits.
Outcomes
Primary Outcome Measures
Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM)
Weekly measurements of expired carbon monoxide in the units of parts per million (PPM) participants to evaluate abstinence from smoking (a value equal to or less than 3 PPM is considered abstinent).
Secondary Outcome Measures
Full Information
NCT ID
NCT02676375
First Posted
February 4, 2016
Last Updated
July 8, 2019
Sponsor
Brentwood Biomedical Research Institute
1. Study Identification
Unique Protocol Identification Number
NCT02676375
Brief Title
Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Official Title
Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
Study Type
Interventional
2. Study Status
Record Verification Date
July 2019
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
June 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brentwood Biomedical Research Institute
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study investigators will enroll 45 treatment seeking, cigarette smokers with a Diagnostic and Statistical Manual (DSM-IV) diagnosis of schizophrenia who will be randomly assigned into three arms of treatment for smoking cessation treatment, receiving either 1. Control: "standard therapy" (n=15), including stepwise monotherapy of nicotine patch or bupropion sustained release, 2. Extended treatment with combination bupropion, nicotine patch, and nicotine lozenge for 6 months (n=15), or 3. Extended treatment with combination bupropion, nicotine patch, and nicotine lozenge for 6 months with home visits (n=15) and phone calls to the home or living facility. During all treatments, participants will receive weekly smoking cessation group counseling, as is standard for smoking cessation treatment. At the time of enrollment, participants will complete a one-study visit lead-in to complete baseline assessments, psychological and medical evaluation, and comprehensive assessment of drug use to determine study eligibility. Once determined to be eligible for the trial, participants will be randomly assigned to one of the treatment arms using a randomization procedure. The "standard therapy" treatment arm, or control group, will receive either nicotine patch taper starting at 21 milligrams (mg) daily, nicotine lozenge as needed, and/or bupropion sustained release at 150mg daily for 3 days, then 150 mg twice a day for a total of 12 weeks. The extended therapy arm will start the nicotine patch at 21mg daily with as needed nicotine lozenge for breakthrough cravings and initiation of bupropion sustained release at 150mg daily for 3 days a week prior to starting nicotine replacement, then 150 mg twice daily for 6 months (as tolerated). The third arm will be identical to the second arm except for the added home visit intervention.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking Cessation, Schizophrenia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
42 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard Monotherapy
Arm Type
Other
Arm Description
Treatment as usual starting with one smoking cessation medication plus group therapy.
Arm Title
Combination Extended Treatment
Arm Type
Experimental
Arm Description
Extended treatment with multiple standard medications plus group therapy.
Arm Title
Combination Extended Treatment + Home Visits/Calls
Arm Type
Experimental
Arm Description
Extended treatment with multiple standard medications plus group therapy plus home visits.
Intervention Type
Drug
Intervention Name(s)
Combination Bupropion + NRTs
Intervention Type
Other
Intervention Name(s)
Extended Treatment
Intervention Type
Other
Intervention Name(s)
Home Visits & Calls
Intervention Type
Drug
Intervention Name(s)
Monotherapy
Primary Outcome Measure Information:
Title
Exhaled Carbon Monoxide (CO) as Parts Per Million (PPM)
Description
Weekly measurements of expired carbon monoxide in the units of parts per million (PPM) participants to evaluate abstinence from smoking (a value equal to or less than 3 PPM is considered abstinent).
Time Frame
Measured week 0, 12, and 26
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Veterans 21 years of age or older;
meet DSM-IV criteria for Schizophrenia or Schizoaffective disorder based on clinical interview
meet DSM-IV criteria for nicotine dependence
must report smoking >10 cigarettes daily and positive CO exhalation >8ppm
seeking treatment for nicotine dependence;
willing and able to comply with study procedures;
willing and able to provide written informed consent;
if female, not pregnant or lactating and willing to use a medically reliable method of birth control during the trial (e.g., birth control pills, Depo-Provera, and/or condoms with spermicide).
Must be clinically stable (i.e., no inpatient hospitalizations for 3 months prior to enrollment, no changes in medication in the four weeks prior to enrollment)
Exclusion Criteria:
current or past history of cardiovascular disease including myocardial infarction, acute coronary syndrome, angina pectoris, coronary artery disease, atrial fibrillation/flutter, cor pulmonale, arrhythmia other than sinus tachycardia or sinus bradycardia, or an EKG suggesting any of these;
systolic blood pressure greater than 160 or diastolic blood pressure greater than 100 (i.e. cutoffs for stage 2 hypertension)
a history of angioedema;
renal impairment (CrCl < 50);
a current neurological disorder (e.g., organic brain disease, dementia) or a medical history which would make study agent compliance difficult or which would compromise informed consent;
a history of attempted suicide (lifetime) and/or suicidal ideation in the past year as assessed by the C-SSRS;
currently on prescription medication that is contraindicated for use with bupropion;
currently using any form of nicotine replacement therapy;
current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by DSM-IV within the past 6 months;
a history of sensitivity to bupropion or nicotine replacement;
any history of seizures or seizure disorder;
a history of serious head injury (ie, loss of consciousness longer than 1 hour, no neuropsychological sequelae, no cognitive rehabilitation treatment post head injury
evidence of substance or alcohol dependence in the past six months; evidence of substance or alcohol abuse in the past month;
sedatives or benzodiazepine use within 12 hours of testing based on urine toxicology screening
history of mental retardation or developmental disability based on chart review
psychiatric hospitalization during study participation
history of an eating disorder
have a medical condition that could be made worse by treatment with nicotine, including poorly controlled insulin dependent diabetes, uncontrolled hyperthyroidism, pheochromocytoma, severe oropharyngeal, esophageal, or peptic ulcer disease, or severe renal or hepatic impairment as determined via the baseline medical history and physical exam
have an allergy to adhesive tape or latex or serious dermatologic disease (excluding minor skin conditions such as mild eczema) due to potential for skin allergy to patch
have a known allergy to nicotine or any component of the nicotine patches
be pregnant or sexually active and not using reliable birth control methods consistently (for females)
Facility Information:
Facility Name
West Los Angeles Veterans Affairs Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90073
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment
We'll reach out to this number within 24 hrs